Related Experiment Video
Updated: Oct 14, 2025
In Vivo Modeling of the Morbid Human Genome using Danio rerio
Published on: August 24, 2013
Clinical features of Danon disease and insights gained from LAMP-2 deficiency models
Yafei Zhai1, Jinxin Miao2, Ying Peng1
1Centre for Cardiovascular Diseases, Henan Key Laboratory of Hereditary Cardiovascular Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, P.R. China.
Abstract:
Danon disease (DD) is an X-linked multisystem disorder with clinical features characterized by the triad of hypertrophic cardiomyopathy, skeletal muscle weakness, and mental retardation. Cardiac involvement can be fatal in the absence of an effective treatment option such as heart transplantation. Molecular studies have proved that LAMP-2 protein deficiency, mainly LAMP-2B isoform, resulting from LAMP2 gene mutation, is the culprit for DD. Autophagy impairment due to LAMP-2 deficiency mediated the accumulation of abnormal autophagic vacuoles in cells. While it is not ideal for mimicking DD phenotypes in humans, the emergence of LAMP-2-deficient animal models and induced pluripotent stem cells from DD patients provided powerful tools for exploring DD mechanism. In both in vitro and in vivo studies, much evidence has demonstrated that mitochondria dysfunction and fragmentation can result in DD pathology. Fundamental research contributes to the therapeutic transformation. By targeting the molecular core, several potential therapies have demonstrated promising results in partial phenotypes improvement. Among them, gene therapies anticipate inaugurate a class of symptom control and prevention drugs as their in vivo effects are promising, and one clinical trial is currently underway.
Insights
Danon disease (DD) is an X-linked disorder caused by LAMP2 gene mutations, leading to cellular dysfunction. Research highlights mitochondrial issues and explores gene therapies for potential treatment.
Area of Science:
- Genetics and Molecular Biology
- Cell Biology
- Cardiovascular Medicine
Background:
- Danon disease (DD) is an X-linked disorder characterized by hypertrophic cardiomyopathy, skeletal muscle weakness, and intellectual disability.
- The primary cause of DD is deficiency in the lysosome-associated membrane protein 2 (LAMP-2) protein, particularly the LAMP-2B isoform, due to mutations in the LAMP2 gene.
- LAMP-2 deficiency impairs autophagy, leading to the accumulation of abnormal autophagic vacuoles within cells.
Purpose of the Study:
- To explore the underlying mechanisms of Danon disease.
- To investigate the role of cellular dysfunction, particularly mitochondrial abnormalities, in DD pathogenesis.
- To review emerging therapeutic strategies targeting the molecular basis of DD.
Main Methods:
- Utilized LAMP-2-deficient animal models and patient-derived induced pluripotent stem cells for in vitro and in vivo studies.
- Examined cellular mechanisms including autophagy impairment and mitochondrial dysfunction.
- Reviewed current research on potential therapeutic interventions for Danon disease.
Main Results:
- Evidence indicates that mitochondrial dysfunction and fragmentation are key contributors to DD pathology.
- Studies in both cellular and animal models have provided insights into the disease mechanisms.
- Several therapeutic approaches targeting molecular pathways have shown promise in improving disease phenotypes.
Conclusions:
- Mitochondrial dysfunction is a significant factor in Danon disease pathology.
- LAMP-2 deficiency-induced cellular defects drive disease progression.
- Gene therapies represent a promising avenue for future treatment of Danon disease, with ongoing clinical trials.
